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Abstract
P2Y2 and P2Y4 receptors are G protein-coupled receptors, activated by UTP and dinucleoside
tetraphosphates, which are difficult to distinguish pharmacologically for lack of potent and
selective ligands. We varied structurally phosphate and uracil moieties in analogues of pyrimidine
nucleoside 5′-triphosphates and 5′-tetraphosphate esters. P2Y4 receptor potency in phospholipase
C stimulation in transfected 1321N1 human astrocytoma cells was enhanced in N4-
alkyloxycytidine derivatives. OH groups on a terminal δ-glucose phosphoester of uridine 5′-
tetraphosphate were inverted or substituted with H or F to probe H-bonding effects. N4-
(Phenylpropoxy)-CTP 16 (MRS4062), Up4-[1]3′-deoxy-3′-fluoroglucose 34 (MRS2927) and N4-
(phenylethoxy)-CTP 15 exhibit ≥10-fold selectivity for human P2Y4 over P2Y2 and P2Y6
receptors (EC50 values 23, 62 and 73 nM, respectively). δ-3-Chlorophenyl phosphoester 21 of Up4
activated P2Y2 but not P2Y4 receptor. Selected nucleotides tested for chemical and enzymatic
stability were much more stable than UTP. Agonist docking at CXCR4-based P2Y2 and P2Y4
receptor models indicated greater steric tolerance of N4-phenylpropoxy group at P2Y4. Thus,
distal structural changes modulate potency, selectivity, and stability of extended uridine
tetraphosphate derivatives, and we report the first P2Y4 receptor-selective agonists.
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Introduction
The eight subtypes of P2Y receptors are nucleotide-activated G protein-coupled receptors
(GPCRs), and four of these subtypes, the P2Y2, P2Y4, P2Y6, and P2Y14 receptors, respond
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to uracil nucleotides.1,2 The P2Y2 and P2Y4 receptors are activated by uridine 5′-
triphosphate (UTP, 1, Chart 1) and its analogues and are difficult to distinguish
pharmacologically, and a prominent need exists for definitive ligand tools.3,4 The P2Y2
receptor also is activated by analogues of adenine 5′-triphosphate.
Dinucleotide P2Y2 receptor agonists, such as 2 (Up4U, INS365), which are more resistant to
enzymatic hydrolysis than 1, are being developed clinically for treatment of eye and
pulmonary diseases.5–7 Compounds 1 and 2 are not selective for the P2Y2 receptor.
However, several studies have explored the structure activity relationship (SAR) of
agonists8, 9–13 and antagonists14 at the P2Y2 receptor, and potent and selective P2Y2
receptor agonists, such as 4 (MRS2698)10 and C-linked nucleotides9 have been identified.
The nucleotide agonists 5 – 7 also are P2Y2 receptor-selective relative to both P2Y4 and
P2Y6 receptors.13 In contrast, the 2′-azido analogue 3 is one of the few analogues of 1 that
displays any selectivity (only 5-fold in comparison to the P2Y2 receptor) for the P2Y4
receptor.8 There are no selective antagonists of the P2Y4 receptor.
In the present study, we further investigated SARs at the P2Y2 and P2Y4 receptors through
synthesis of nucleotides with additional substitutions of the uracil and phosphate moieties
and combinations thereof. These novel derivatives incorporated groups such as 4-
methoxyimino and its homologues on the pyrimidine ring, found previously to enhance the
potency of analogues of uridine 5′-diphosphate (UDP) at P2Y receptors.15 We also probed
the effects of substituting one uridine moiety of 2 with various sugar and aliphatic and
aromatic alcohol moieties. Two lead δ -phosphoesters of 5′-tetraphosphates that were
recently reported as full agonists of the P2Y2 receptor,13 i.e. 7 (MRS2768), which was P2Y2
receptor-specific, and 8 (MRS2732), with 7- and 26-fold selectivity in comparison to P2Y4
and P2Y6 receptors, were modified in the present study. Although P2Y2 receptor selectivity
was not improved by these changes, several analogues exhibited important increases in
potency and selectivity at the P2Y4 receptor. This new chemical synthesis was combined
with molecular docking studies based on a model derived from the recently solved structure
of the CXCR4 chemokine receptor16 to interrogate the molecular basis for selectivity of
interaction of several of these molecules for the P2Y4 receptor over the P2Y2 receptor.
Results
Chemical Synthesis
Novel nucleotide derivatives (Tables 1) were prepared by the synthetic routes shown in
Schemes 1 – 6. The potencies of nine known reference compounds (1, 6–9, 17–19 and 27)
are also listed in Table 1.11–13 The types of nucleotide modifications made included:
analogues of cytidine 5′ -triphosphate (CTP) containing a N4-alkoxy group (Scheme 1); 5′-
tetraphosphates derivatives of 17 (Up4) containing a substituted δ-phenyl phosphoester
group at the terminal phosphate (Scheme 2 and 5); derivatives of 17 containing a sugar
group at the terminal phosphate (Scheme 3 and 6); analogues of 1 containing a β,γ-
dichloromethylene-bridge in the triphosphate group (Scheme 4).
The synthesis of N4 -alkoxy cytidines 39 – 42 from cytidine was performed using
corresponding alkoxy amines. The resulting N4 -alkoxy cytidines were phosphorylated by
standard methods6 to give the desired N4 -alkoxy-CTP analogues 11 – 16 (Scheme 1). In
each case, the unprotected nucleoside was first treated with phosphorous oxychloride, and
the reaction mixture was treated immediately with bis(tri-n-butylammonium) pyrophosphate
to produce the 5′-triphosphate. The favored method for preparation of the β, γ-
dichloromethylene derivative 10 was by condensation of dichloromethylenediphosphonic
acid with uridine-5′-monophosphate (UMP) using N,N′-diisopropylcarbodiimide (DIC). An
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alternate method involving reaction with UMP-morpholide required two weeks of reaction
to reach completion.
The synthesis of 5′-tetraphosphate derivatives that were modified at the terminal phosphates
was performed using a carbodiimide coupling reagent in the presence of magnesium
chloride (Schemes 5 and 6). The addition of MgCl2 dramatically increased the reactivity
during the coupling reaction of monophosphate and triphosphate,17 but it impeded the
coupling of monophosphate and diphosphate (data not shown). Phenyl monophosphates 57 –
62 were prepared by phosphorylation with a dibenzyl-protected phosphate group followed
by deprotection of the benzyl groups using trimethylsilyl bromide (TMS-Br, Scheme 2).15
Hexose sugar monophosphates 68 – 72 were phosphorylated at the 1′-position by full
acetylation and treatment with phosphoric acid. The synthesis of glucuronic acid-1-
monophosphate 74 was performed by oxidation of commercially available glucose-1-
monophosphate using 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) as a catalyst.18
Pharmacological Activity
Activation of phospholipase C (PLC) by a range of concentrations of each newly
synthesized nucleotide derivative (10 – 37) was studied in [3H]inositol-labeled 1321N1
human astrocytoma cells stably expressing the human P2Y2, P2Y4, or P2Y6 receptor by
following methodology (see Experimental Section) we described previously in detail.13,15,19
Table 1 illustrates analogues of 1 and 17 that were designed for possible interaction with the
P2Y2 and P2Y4 receptors and their biological potencies. Introduction of β,γ-
phosphonomethylene bridges, which enhances stability of nucleotides against the action of
ectonucleotidases, resulted in compounds 6 and 10 that were inactive at the P2Y4 receptor.13
The possibility of a hydrophobic pocket beyond the 4 position of the pyrimidine ring in the
P2Y2 or P2Y4 receptor structure was probed in analogues of 1 with N4-alkoxyimino
moieties 11 – 16. One of these molecules, N4-methoxy-CTP 11,15 was more potent than the
native ligand 1 at both subtypes. Within a related series of homologous arylalkoxy
derivatives, the N4-phenylpropoxy substitution of CTP in 16 was found to optimally
increase activity at the P2Y4 receptor with an EC50 value of 23 nM (Figures 1 and 2). This
compound displayed selectivities of 28-fold and 32-fold in comparison to the P2Y2 and
P2Y6 receptors, respectively. N4-Phenylethoxy substitution of CTP resulted in a molecule
15 that exhibited somewhat lower potency (EC50 = 73 nM) and selectivity (16-fold and 17-
fold in comparison to the P2Y2 and P2Y6 receptors, respectively) than 16 for the P2Y4
receptor.
Introduction of either a sugar moiety or a substituted phenyl ring at the terminal δ-phosphate
was examined in the series of 5′-tetraphosphates. We previously reported that introduction
of a glucose or phenyl ester group at the δ-phosphate resulted in increased selectivity for the
P2Y2 receptor against the P2Y4 and P2Y6 receptors.13 A 3-Cl derivative 21 showed higher
potency than the phenyl derivative 7, but its P2Y2 receptor selectivity in comparison to the
P2Y6 receptor was decreased. Similarly, all substitutions of the δ-phenyl ester examined (20
– 25) were either less potent or less selective for the P2Y2 receptor than the unsubstituted 7.
Consistent with previous findings, introduction of a β,γ-dichloromethylene substitution in 24
abolished activity at the three P2Y receptors tested. Based on the P2Y2 receptor selectivity
of Up4-δ-[1]glucose 8,13 substitutions of the δ -glucose moiety were examined (26 – 37).
The types of glucose modifications included were inversion of hydroxyl groups (27 – 29),
replacement of a hydroxyl group with F (33 – 37), and other omission or other replacement
of hydroxyl functionality (30 – 32). These modifications resulted in greatly varied potency
and selectivity for the P2Y receptors. Inversion of the 3′-hydroxyl group in the allose
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derivative 28 increased P2Y4 receptor potency 11-fold, but inversion of the 2′-hydroxyl
group in the mannose derivative 29 decreased potency at P2Y2, P2Y4, and P2Y6 receptors.
Fluoro substitution at the 2′ position of the terminal δ-glucose moiety in 33 greatly reduced
activity at all three receptor subtypes, suggesting that the H-bond-donating property of the
2′-hydroxyl group is necessary for this biological activity. The hydroxymethylene group
appeared to be important for activity at the P2Y2 receptor, because the xylose derivative 30
exhibited reduced activity (9-fold less potent than 8) at this subtype.
The 3′- and 4′-fluoro derivatives 34 and 37 maintained activity at the P2Y2 receptor.
However, fluoro substitution at the 3′ position of the terminal glucose moiety in 34 greatly
increased potency (EC50 = 62 nM) at the P2Y4 receptor. Thus, P2Y4 receptor selectivities of
11.5-fold and 15.3-fold were observed for this analogue in comparison to the P2Y2 and
P2Y6 receptors, respectively. Analogues 35 and 36 that included combination of 3′-
deoxy-3′-fluoroglucose with the N4-benzyloxyimino or N4-methoxyimino modification in
the nucleobase were less active and selective than unmodified 34. Thus, simultaneous
introduction of these two P2Y4 receptor-directing modifications did not produce further
enhancement of potency or selectivity.
Molecular Modeling
In light of the SAR data generated through this work, in particular the different selectivity
profile of compounds 11 and 16, we revised our experimentally supported modeling
hypothesis for the binding model of pyrimidine-based nucleotides to the P2Y2 and P2Y4
receptors, through the incorporation of further experimental data. These new models were
not used to design the compounds but to offer a putative structural interpretation of the
results. Note: to facilitate the comparison among receptors, throughout this section amino
acid residues are designated both with their residue number in the P2Y2 and P2Y4 sequence
as well as the universal GPCR residue identifier defined by the Ballesteros and
Weinstein.20,28,29
In the absence of experimentally elucidated structures of any of the members of the P2Y
family, in the last decade we have constructed models of the P2Y2 and P2Y4 receptors
through homology modeling based on rhodopsin, which, at the time, was the only
crystallographically solved GPCR, followed by molecular docking.8,10,20 We incorporated
into the models several hypotheses derived from experiments. These included the presence
of two disulfide bridges and a salt bridge that putatively contribute to the shape of the
extracellular domains of the receptors. Data from mutagenesis studies revealed that the
residues involved in formation of these extracellular bridges are fundamental to the function
of P2Y receptors.22–24 The binding mode of the ligand was also driven by mutagenesis and
SAR data. Specifically, our published models were constructed using as anchors for the
binding of the phosphate moieties of the nucleotides three cationic residues located in TM3,
TM6, and TM7 that are essential for ligand recognition according to mutagenesis data.24–26
The Northern (N) conformation adopted by the ribose moiety of 1 and the orientation of the
nucleobase toward the opening of the interhelical cavity are also supported by SAR
data.11,15,21
Our rhodopsin-based models do not explain the different selectivity profiles of compounds
11 and 16, because in those models the area that surrounds the N4-substituents of the two
compounds is completely conserved between the P2Y2 and P2Y4 receptors (Figure 3). Here,
we propose revised models of the P2Y2 and P2Y4 receptors that incorporate the
experimentally supported features of the previous models and are consistent with SAR data
gathered in this work. The new models are based on the recently solved x-ray crystal
structure of the CXCR4 chemokine receptor,16 which, among all those currently available, is
the closest to the P2Y receptors.20 Among the crystallographically solved GPCRs, this
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receptor shares the highest sequence similarity with P2Y receptors, showing 24.6% and
25.7% of sequence identity with the P2Y2 and the P2Y4 receptor – the sequence identity was
calculated according to the alignment shown in Figure 4 and refers to the entire portion of
the CXCR4 receptor that was solved crystallographically, with the exclusion of the C-
terminal domain. Moreover, the CXCR4 contains a disulfide bridge, putatively present also
in the P2Y2 and P2Y4 receptors, connecting the N-terminus (through a Cys located two
positions upstream when compared to the P2Ys) with the boundary between EL3 and TM7
(through a Cys located at position 7.25, as in the P2Y receptors) – see Figure 4. Before the
solution of the CXCR4 structure, none of the structurally characterized GPCRs featured a
similar disulfide bridge. Like the previous rhodopsin-based models, our current models
incorporate all the experimentally derived structural features mentioned above, including the
aforementioned pair of extracellular disulfide bridges and the salt bridge connecting EL2
with the extracellular end of TM6. These features, contribute to shaping of the opening of
the interhelical cavity lined by residues located in the extracellular N-terminus, the three
extracellular loops, and all of the TMs (Figure 5).
We used the new CXCR4-based in silico structures of the P2Y2 and P2Y4 receptors to
construct models of the putative complexes of the two receptors with compounds 11 and 16.
Importantly, we incorporated in the binding mode and in the conformation of the two
ligands all the experimentally supported features shown in our previous models.8,10,20
Moreover, we incorporated novel experimental information that we gathered through NMR
spectroscopy and X-ray crystallography. Specifically, the tautomeric form of the imino
group and its conformation were determined through NMR spectroscopy (chemical shift of
NH at 3 position of 39 and Nuclear Overhauser Effect between MeO and the NH).
Additionally, an x-ray crystallographic structure was obtained for N4-t-BuO-cytosine
(Supporting Information), which is in close agreement with a literature report for N4- MeO-
cytosine.27 The data clearly showed the presence of a hydrogen atom at the 3 position and
the absence of an hydrogen atom at the N4 position. Bond lengths also indicate that that the
compound adopts an exo-double bond tautomeric form.
Interestingly, the new models show several distinctive features that make them compatible
with the selectivity profile compounds 11 and 16 for the P2Y2 and P2Y4 receptors.
Specifically, the binding of nucleotides appears shifted toward the extracellular side in the
new CXCR4-based models compared to those previously reported (Figure 6).8,10,20 This is
due to the fact that in the new models the side chain of Phe3.32 (113 for P2Y2, 115 for P2Y4)
– a residue common to all P2Y receptors and conserved as an aromatic residue (Tyr1163.32)
in the CXCR4 receptor – is parallel to the plane of the membrane. Due to this orientation,
which is consistent with the one shown by Tyr1163.32 in the crystal structure of the CXCR4
receptor, Phe3.32 limits the depth of the binding cavity and prevents the ligands from
docking at a position more distal to the extracellular side. Our previous models, which were
built prior to the availability of a template containing an aromatic residue at position 3.32,
featured the side chain of Phe3.32 oriented perpendicularly to the plane of the membrane
and in π-stacking with the nucleobase of the ligands and allowed for a deeper binding
pocket.8,10,20 Because of the shallower binding mode proposed here in comparison to our
previous rhodopsin-based models, the CXCR4-based models are compatible with the
influence of the substituent at position 4 of the pyrimidine ring on the selectivity of newly
synthesized compounds for P2Y2 and P2Y4 receptors (Figure 5). In particular, the phenyl
moiety of the N4 substituent of compound 16 protrudes toward EL2, fitting into a cavity
lined by two EL2 residues, namely Thr182 and Leu184 in the P2Y4 receptor. These two
residues are not conserved in the P2Y2 receptor, where their place is taken by Arg180 and
Thr182, respectively. Our models suggest that these differences may account for the P2Y4
receptor-selectivity of 16, especially in light of the fact that the sterically bulky Arg180,
conserved in the CXCR4 receptor and oriented as in the CXCR4 crystal structure, seems to
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considerably reduce the volume of the cavity of the P2Y2 receptor. As evident from Figure
5, this is the only region of the interhelical cavity that shows a significantly smaller volume
in the P2Y2 than in the P2Y4 receptor.
Stability of Nucleotide Derivatives
Chemical and enzymatic instability of nucleotide analogues in biological systems is a major
limitation in their use as pharmacological probes. Therefore, selected nucleotide derivatives
were evaluated for stability during prolonged exposure to two different conditions. The
derivatives were incubated at 37°C in aqueous medium at either low pH or in the presence
of membranes prepared from 1321N1 human astrocytoma cells,15 which contain
ectonucleotidases and are representative of cells of the mammalian central nervous system.
At regular intervals aliquots were taken for HPLC analysis (Figure 7).
All the nucleotide analogues tested were more stable in the presence of cell membranes than
the native agonist 1, and the most stable in the group was the Up4-δ-phenyl ester 7. The 4-
chlorophenyl analogue 20 appeared to be more stable than the corresponding 4-methoxy 22
and 4-nitro 24 analogues. Among the nucleotide analogues tested, only Up4-[1]glucose 8
was less stable at pH 1.5 than 1. In general, the Up4-δ-phenyl esters displayed a relatively
high degree of stability under both conditions in comparison to 1. Stability at pH 1.5 was
also determined for the potent P2Y4 receptor agonists 15, 16, and 34. The 5′-triphosphate
derivatives 15 and 16 were similar in stability to 1, and 34 was much more labile, similar to
the closely related δ-glucose phosphoester 8 (Supporting Information).
Discussion
Pharmacological resolution of responses mediated by P2Y2 versus P2Y4 receptors has been
problematic due to lack of selective antagonists and the fact that many analogues of 1 and
diuridine tetraphosphates activate both subtypes. Two classical, general antagonists for P2
receptors, suramin and Reactive Blue 2, have been used as slightly selective antagonists of
the P2Y2 and P2Y4 receptors, respectively.4,31,32 In the rat, inosine-5′-triphosphate was
shown to be 13-fold selective as an agonist at the P2Y4 receptor in comparison to the P2Y2
receptor.32 The work described here identifies modifications that provide important new
directions for introduction of agonist selectivity for P2Y4 receptor ligands.
The P2Y4 receptor is often expressed in the same tissues, or in some cases the same cells, as
the widely distributed P2Y2 receptor. This is the case for epithelial cells of the intestine. The
study of knockout mice has revealed that the stimulatory effect of 1 on chloride secretion is
mediated by the P2Y4 receptor,33,34 whereas its inhibitory effect on sodium absorption
involves the P2Y2 receptor.35 Protective effects of P2Y4 receptor activation were observed
during cardiac ischemia studied in murine HL-1 myocytes.36 P2Y4 mRNA is expressed in
microvascular endothelial cells isolated from mouse heart but not lung.37 The effects of 1 on
migration, proliferation, and VCAM-1 expression in these cells were greatly reduced in
P2Y4 receptor-deficient mice.37 Macrophage adhesion induced by 1 also was reduced, and
P2Y4 receptor-null mice displayed defective angiogenesis in in-vivo models.37 In contrast,
P2Y2 receptor-deficient mice exhibit reduced effects of 1 on leukocyte adhesion, eosinophil
migration, and VCAM-1 expression.38 Thus, selective P2Y4 receptor agonists might prove
useful in the treatment of constipation, cardiac ischemia or inflammation, and exhibit
reduced proinflammatory effects in the lung due to lack of interaction with the P2Y2
receptor.
Substitutions at the 4 position of the nucleobase were explored through the synthesis of
imino derivatives of various sizes. The exploration of this region, done through a classic
medicinal chemistry approach, was prompted by the observation, based on published models
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of the P2Y2 and P2Y4 receptors,8,10,20 that there might have been some space available for
the expansion of the ligands around that position. This process led to the synthesis of the
first P2Y4-selective compounds. In particular, while N4-(methyl)-CTP (11) was unselective
for the two subtypes, N4-(phenylpropoxy)-CTP (16), and N4-(phenylethoxy)-CTP (15) were
selective for the P2Y4 receptor with EC50 values of 23 and 73 nM, respectively. The activity
of these CTP analogues contrasts with the weak interaction of CTP itself at the P2Y2 and
P2Y4 receptors.8 Because our rhodopsin-based models could not explain the different
selectivity profiles of the alkoxyimino derivatives, we reconstructed molecular models of the
P2Y2 and P2Y4 receptors based on the recently disclosed structure of the CXCR4 receptor
(Figure 5).16 The new models incorporate all the experimentally supported features of the
old ones but show a binding mode in which the ligands are slightly shifted towards the
extracellular side (Figure 6), which makes them compatible with the new data. In particular,
the large substituent of compounds 16 protrudes toward EL2, fitting into a cavity
substantially larger in the P2Y4 receptor than in the P2Y2 receptor, due to the non-
conservation of two specific residues. This hypothesis is in good agreement with the
selectivity for the P2Y4 receptor shown by compound 16.
Moreover, by carefully probing substitution of Up4-[1]glucose, we identified Up4-[1]3′-
deoxy-3′-fluoroglucose (34) as modestly P2Y4 selective (EC50 value 62 nM). However,
neither δ-phenyl esters nor methylenephosphonates were useful for achieving selectivity for
the P2Y4 receptor. Up4-δ-3-chlorophenyl ester 21 was inactive at P2Y4 receptors and
displayed an EC50 value at the P2Y2 receptor of 0.84 µM. The chemical and enzymatic
stability of selected derivatives in this series was examined by HPLC to indicate greatly
enhanced stability of the δ-phenyl phosphoesters but not the δ-glucose phosphoesters in
comparison to 1. Thus, additional SAR studies will be needed to enhance the stability of
P2Y4-receptor selective agonists. In particular, these studies suggest that the potency,
selectivity, and stability of extended uridine tetraphosphate derivatives may be modulated by
distal structural changes. N4-Alkoxyimino analogues were analyzed in a molecular model,
which indicated greater steric tolerance of the N4-phenylpropoxy group in the P2Y4
receptor.
In conclusion, we have synthesized novel uracil nucleotide derivatives that are directed
toward selective activation of the P2Y4 receptor. A series of homologous alkoxyimino
derivatives provided an entry to novel selectivity at this subtype. Several of these
compounds should be suitable for use as pharmacological probes of the physiological roles
of the P2Y4 receptor.
Experimental Section
Chemical Synthesis
1H NMR spectra were obtained with a Varian Gemini 300 or Varian Mercury 400
spectrometers using D2O, CDCl3 or DMSO-d6 as a solvent. The chemical shifts are
expressed as relative ppm from HOD (4.80 ppm). 31P NMR spectra were recorded at rt by
use of Varian XL 300 (121.42 MHz) or Varian Mercury 400 (162.10 MHz) spectrometers;
orthophosphoric acid (85%) was used as an external standard. In several cases the signal of
the terminal phosphate moiety was not visible due to high dilution.
The purity of final nucleotide derivatives was checked using a Hewlett–Packard 1100 HPLC
equipped with a Zorbax SB-Aq 5 µm analytical column (50 × 4.6 mm; Agilent Technologies
Inc, Palo Alto, CA). Mobile phase: linear gradient solvent system: 5 mM TBAP
(tetrabutylammonium dihydrogenphosphate)-CH3CN from 80:20 to 40:60 in 13 min; the
flow rate was 0.5 mL/min. Peaks were detected by UV absorption with a diode array
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detector at 254, 275, and 280 nm. All derivatives tested for biological activity showed >97%
purity by HPLC analysis (detection at 254 nm).
High-resolution mass measurements were performed on Micromass/Waters LCT Premier
Electrospray Time of Flight (TOF) mass spectrometer coupled with a Waters HPLC system,
unless noted. Purification of the nucleotide analogues for biological testing was carried out
on (diethylamino)ethyl (DEAE)-A25 Sephadex columns with a linear gradient (0.01–0.5 M)
of 0.5 M ammonium bicarbonate as the mobile phase. Compounds 10 was purified by
Sephadex alone (and isolated in the ammonium salt form), and compounds 11 – 16 were
additionally purified by HPLC with a Luna 5 µ RP-C18(2) semipreparative column (250 ×
10.0 mm; Phenomenex, Torrance, CA) and using the following conditions: flow rate of 2
mL/min; 10 mM triethylammonium acetate (TEAA)-CH3CN from 100:0 to 95:5 (System A)
(or up to 99:1 to 50:50 (System B)) in 30 min (and isolated in the triethylammonium salt
form). All other compounds were purified only by HPLC. All other reagents were of
analytical grade, and were purchased from Sigma-Aldrich (St. Louis, MO).
Uridine-5′-β,γ-dichloromethylene triphosphate ammonium salt (10)—Uridine
monophosphate sodium salt (300 mg, 0.93 mmol) and the dichloromethylenediphosphonic
acid disodium salt (1 g, 3.46 mmol) were converted to the tributylammonium salts by
treatment with ion-exchange resin (DOWEX 50WX2-200 (H)) and tri-n-butylamine. After
removal of the water, the obtained tributylammonium salts were dried under high vacuum
for 1 h. DIC (76.20 µL, 0.90 mmol) was added to a solution of uridine monophosphate
tributylammonium salt (0.93 mmol) in DMF (3 mL). After stirring the reaction mixture at rt
for 3 h, a solution of dichloromethylenediphosphonic acid tributylammonium salt (3.46
mmol) and MgCl2 (171.4 mg, 1.8 mmol) in DMF (2 mL) was added. The reaction mixture
was stirred at rt overnight. After removal of the solvent, the MgCl2 was removed by
treatment with ion-exchange resin (DOWEX 50WX2-200 (H)) and ammonia bicarbonate,
and the product 10 was purified by ion-exchange column chromatography with a Sephadex-
DEAE A-25 resin. 1H NMR (D2O) δ 7.96 (d, J = 7.8 Hz, 1H), 5.96 (m, 2H), 4.43 (m, 1H),
4.37 (m, 1H), 4.36 (m, 2H); 31P NMR (D2O) δ −7.77 (d, J = 18.3 Hz), −10.54 (s), −10.79
(s); HRMS-EI found 548.9043 (M-H)+. C10H14Cl2N2O14P3 requires 548.9035; HPLC RT
9.7 min (99%) in solvent system A, 1.1 min (98%) in system B.
General procedure for the preparation of nucleoside triphosphates (11–16)
A solution of the nucleoside 39–4415 (0.073 mmol) and Proton Sponge (24 mg, 0.11 mmol)
in trimethyl phosphate (0.4 mL) was stirred for 10 min at 0 °C. Then, phosphorous
oxychloride (0.013 mL, 0.13 mmol) was added dropwise, and the reaction mixture was
stirred for 2 h at 0 °C. A solution of tributylammonium pyrophosphate (0.8 mL, 0.44 mmol)
and tri-n-butylamine (0.069 mL, 0.29 mmol) in N,N-dimethylformamide (DMF, 1 mL) was
added and stirring was continued at 0°C for additional 10 min. 0.2 M Triethylammonium
bicarbonate solution (1.5 mL) was added, and the clear solution was stirred at rt for 1 h.
After removal of solvents, the residue was purified by Sephadex-DEAE A-25 resin and
preparative HPLC.
N4-Methoxycytidine-5′-triphosphate triethylammonium salt (11)—Compound 11
(37.6 mg, 100%) was obtained as a white solid using N4-methoxycytidine 39 (20 mg, 0.073
mmol). 1H NMR (D2O) δ 7.26 (d, J = 8.2 Hz, 1H), 5.96 (d, J = 6.4 Hz, 1H), 5.82 (d, J = 8.2
Hz, 1H), 4.46-4.41 (m, 1H), 4.41-4.37 (m, 1H), 4.28-4.15 (m, 3H), 3.80 (s, 3H); 31P NMR
(D2O) δ −11.39 (br), −22.90 (br); HRMS-EI found 511.9873 (M – H+)−. C10H17N3O15P3
requires 511.9857; purity > 98% by HPLC (System B: 9.08 min).
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N4-Ethoxycytidine-5′-triphosphate triethylammonium salt (12)—Compound 12
(21.3 mg, 58%) was obtained as a white solid using N4-ethoxycytidine 40 (20 mg, 0.070
mmol). 1H NMR (D2O) δ 7.26 (d, J = 7.8 Hz, 1H), 5.96 (d, J = 6.6 Hz, 1H), 5.82 (d, J = 7.8
Hz, 1H), 4.47-4.42 (m, 1H), 4.41-4.34 (m, 1H), 4.28-4.22 (m, 2H), 4.21-4.13 (m, 1H), 4.05
(dd, J = 14.2, 7.1 Hz, 2H); 31P NMR (D2O) δ - 11.29 (br), −22.10 (br); HRMS-EI found
526.0029 (M – H+)−. C11H19N3O15P3 requires 526.0029; purity > 98% by HPLC (System
B: 10.6 min).
N4-t-Butyloxycytidine-5′-triphosphate triethylammonium salt (13)—Compound
13 (7.6 mg, 22%) was obtained as a white solid using N4-t-butoxycytidine 41 (20 mg, 0.063
mmol). 1H NMR (D2O) δ 7.24 (d, J = 8.2 Hz, 1H), 5.97 (d, J = 6.4 Hz, 1H), 5.87 (d, J = 8.2
Hz, 1H), 4.43-4.35 (m, 2H), 4.26-4.12 (m, 3H), 1.31 (s, 9H); 31P NMR (D2O) δ −9.85 (br),
−11.36 (br), −22.99 (br); HRMS-EI found 554.0342 (M – H+)−. C13H23N3O15P3 requires
554.0341; purity > 98% by HPLC (System B: 9.59 min).
N4-Benzyloxycytidine-5′-triphosphate triethylammonium salt (14)—Compound
14 (16.7 mg, 49%) was obtained as a white solid using N4-benzyloxycytidine 42 (20 mg,
0.057 mmol). 1H NMR (D2O) δ 7.46-7.35 (m, 5H), 7.22 (d, J = 8.4 Hz, 1H), 5.95 (d, J = 6.5
Hz, 1H), 5.76 (d, J = 8.4 Hz, 1H), 5.05 (s, 2H), 4.43-4.32 (m, 2H), 4.26-4.13 (m, 3H); 31P
NMR (D2O) δ −10.18 (br), −11.56 (d, J = 14.6 Hz), −23.21(t, J = 15.0 Hz); HRMS-EI
found 588.0186 (M – H+)−. C16H21N3O15P3 requires 588.0200; purity > 98% by HPLC
(System B: 10.14 min).
N4-Phenylethoxycytidine-5′-triphosphate triethylammonium salt (15)—
Compound 15 (1.29 mg, 5.5%) was obtained as a white solid using N4-(2-phenylethoxy)-
cytidine 43 (10 mg, 0.027 mmol). 1H NMR (D2O) δ 7.40-7.29 (m, 5H), 7.23 (d, J = 7.6 Hz,
1H), 5.94 (d, J = 6.0 Hz, 1H), 5.81 (d, J = 8.4 Hz, 1H), 4.43-4.38 (m, 2H), 4.28-4.25 (m,
5H), 3.00 (dd, J = 6 Hz, J = 6.4 Hz); HRMS-EI found 602.0342 (M – H+)−. C17H23N3O15P3
requires 602.0318; purity > 98% by HPLC.
N4-Phenylpropoxycytidine-5′-triphosphate triethylammonium salt (16)—
Compound 16 (0.83 mg, 11%) was obtained as a white solid using N4-(3-phenylpropoxy)-
cytidine 44 (5 mg, 0.013 mmol). 1H NMR (D2O) δ 7.38-7.31 (m, 5H), 7.23 (d, J = 8.4 Hz,
1H), 5.95 (d, J = 6.0 Hz, 1H), 5.78 (d, J = 8.4 Hz, 1H), 4.42-4.38 (m, 2H), 4.25-4.23 (m,
3H), 4.06 (dd, J = 5.5 Hz, J = 6.1 Hz, 2H), 2.75 (dd, J = 7.28 Hz, J = 7.45 Hz, 2H), 4.20 (m,
2H); 31P NMR (D2O) δ −5.51 (m), −10.34 (m), −10.81 (m); HRMS-EI found 616.0486 (M
– H+)−. C18H25N3O15P3 requires 616.0496; purity > 98% by HPLC.
General procedure for the preparation of nucleoside tetraphosphate phenyl derivatives
(20–25)
The corresponding aryl monophosphate15 (0.036 mmol) and 1 as a trisodium salt (10 mg,
0.018 mmol) were converted to the tributylammonium salts by treatment with ion-exchange
resin (DOWEX 50WX2-200 (H)) and tri-n-butylamine. After removal of the water, the
obtained tributylammonium salts were dried under high vacuum for 1 h. DIC (3.05 µL,
0.036 mmol) was added to a solution of uridine triphosphate tributylammonium salt (0.018
mmol) in DMF (0.2 mL). After stirring the reaction mixture at rt for 1 h, a solution of the
corresponding aryl monophosphate tributylammonium salt (0.036 mmol) and MgCl2 (3.43
mg, 0.036 mmol) in DMF (0.1 mL) was added. The reaction mixture was stirred at rt
overnight. After removal of the solvent, the MgCl2 was removed by treatment with ion-
exchange resin (DOWEX 50WX2-200 (H)) and ammonia bicarbonate or tri-n-butylamine,
and the residue was purified by a semipreparative HPLC.
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Uridine-5′-(4-chlorophenyl)-tetraphosphate triethylammonium salt (20)—
Compound 20 (0.3 mg, 6%) was obtained as a white solid using 1 (12 mg, 0.022 mmol). 1H
NMR (D2O) δ 7.93 (d, J = 7.5 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H),
5.97 (d, J = 5.4 Hz, 1H), 5.93 (d, J = 7.8 Hz, 1H), 4.42-4.30 (m, 2H), 4.27-4.21 (m, 3H); 31P
NMR (D2O) δ −11.20 (br), −15.74 (br), −23.04 (br); HRMS-EI found 672.9218 (M – H+)−.
C15H18N2O18P4Cl requires 672.9194; purity > 98% by HPLC (System B: 11.9 min).
Uridine-5′-(3-chlorophenyl)- tetraphosphate triethylammonium salt (21)—
Compound 21 (1.4 mg, 12%) was obtained as a white solid using 1 (10 mg, 0.018
mmol). 1H NMR (D2O) δ 7.88 (d, J = 8.1 Hz, 1H), 7.36-7.12 (m, 4H), 5.91 (d, J = 5.1 Hz,
1H), 5.79 (d, J = 8.1 Hz, 1H), 4.39-4.28 (m, 2H), 4.23-4.17 (m, 3H); 31P NMR (D2O) δ
−11.20 (d, J = 18.3 Hz), −15.84 (d, J = 17.5 Hz), −23.14 (m); HRMS-EI found 672.9218
(M – H+)−. C15H18N2O18P4Cl requires 672.9194; purity > 98% by HPLC (System B: 12.2
min).
Uridine-5′-(4-methoxyphenyl)- tetraphosphate triethylammonium salt (22)—
Compound 22 (2.7 mg, 22%) was obtained as a white solid using 1 (10 mg, 0.018
mmol). 1H NMR (D2O) δ 7.88 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 9.0 Hz, 2H), 6.92 (d, J = 9.0
Hz, 2H), 5.91 (d, J = 5.1 Hz, 1H), 5.88 (d, J = 8.4 Hz, 1H), 4.37-4.25 (m, 2H), 4.23-4.16 (m,
3H), 3.78 (s, 3H); 31P NMR (D2O) δ −11.19 (br, 1H), −15.04 (br, 1H), −23.00 (br, 2H);
HRMS-EI found 668.9681 (M – H+)−. C16H21N2O19P4 requires 668.9689; purity > 98% by
HPLC (System A: 12.1 min).
Uridine-5′-(3-methoxyphenyl)- tetraphosphate triethylammonium salt (23)—
Compound 23 (1.9 mg, 16%) was obtained as a white solid using 1 (10 mg, 0.018
mmol). 1H NMR (D2O) δ 7.89 (d, J = 8.1 Hz, 1H), 7.26 (t, J = 8.1 Hz, 1H), 6.90-6.82 (m,
2H), 6.72 (d, J = 8.1 Hz, 1H), 5.91 (d, J = 6.0 Hz, 1H), 5.88 (d, J = 8.7 Hz, 1H), 4.38-4.24
(m, 2H), 4.22-4.16 (m, 3H), 3.80 (s, 3H); 31P NMR (D2O) δ −11.20 (d, J = 18.4 Hz, 1H),
−15.69 (d, J = 17.5 Hz, 1H), −23.14 (m, 2H); HRMS-EI found 668.9699 (M – H +)−.
C16H21N2O19P4 requires 668.9689; purity > 98% by HPLC (System A: 12.1 min).
Uridine-5′-(4-nitrophenyl)- tetraphosphate triethylammonium salt (24)—
Compound 24 (2.2 mg, 23%) was obtained as a white solid using 1 (12 mg, 0.022
mmol). 1H NMR (D2O) δ 8.23 (d, J = 8.7 Hz, 2H), 7.87 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.7
Hz, 2H), 5.91 (d, J = 5.1 Hz, 1H), 5.87 (d, J = 8.4 Hz, 1H), 4.37-4.28 (m, 2H), 4.22- 4.17
(m, 3H); 31P NMR (D2O) δ-11.14 (d, J = 17.5 Hz, 1H), −16.83 (d, J = 16.9 Hz, 1H), −23.06
(m, 2H); HRMS-EI found 683.9434 (M – H +)−. C15H18N3O20P4 requires 683.9434; purity
> 98% by HPLC (System A: 11.6 min).
Uridine-5′-(3-nitrophenyl)- tetraphosphate triethylammonium salt (25)—
Compound 25 (3.4 mg, 41%) was obtained as a white solid using 1 (10 mg, 0.018
mmol). 1H NMR (D2O) δ 8.27 (d, J = 12.0 Hz, 2H), 7.92 (d, J = 8.1 Hz, 1H), 7.44 (d, J =
12.0 Hz, 2H), 5.96-5.88 (m, 2H), 4.41-4.30 (m, 2H), 4.25-4.19 (m, 3H); 31P NMR (D2O)
δ-11.18 (d, J = 14.5 Hz), −16.89 (d, J = 14.5 Hz), −22.80 − 23.60 (m); HRMS-EI found
683.9434 (M – H)−. C15H18N3O20P4 requires 683.9438; purity > 98% by HPLC (System A:
13.1 min).
Uridine-5′-glucose-1′-β,γ-dichloromethylene tetraphosphate
triethylammonium salt (26)—Compound 10 (3.4 mg, 0.006 mmol) and glucose-1-
phosphate disodium salt hydrate (4 mg, 0.036 mmol) were converted to the
tributylammonium salts by treatment with ion-exchange resin (DOWEX 50WX2-200 (H))
and tri-n-butylamine. After removal of the water, the obtained tributylammonium salts were
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dried under high vacuum for 1 h. DIC (3.05 µL, 0.036 mmol) was added to a solution of 10
(0.006 mmol) in DMF (0.2 mL). After stirring the reaction mixture at rt for 1 h, a solution of
glucose-1-phosphate tributylammonium salt (0.036 mmol) and MgCl2 (3.43 mg, 0.036
mmol) in DMF (0.1 mL) was added. The reaction mixture was stirred at rt overnight. After
removal of the solvent, the MgCl2 was removed by treatment with ion-exchange resin
(DOWEX 50WX2-200 (H)) and ammonia bicarbonate or tri-n-butylamine, and the residue
was purified by a semipreparative HPLC to obtain 26 (0.32 mg, 7%) as a white solid. 1H
NMR (D2O) δ 8.02 (d, J = 8.1 Hz, 1H), 6.04-5.97 (m, 2H), 5.71-5.67 (m, 1H), 4.53-4.47 (m,
1H), 4.44-4.38 (m, 1H), 4.37-4.25 (m, 3H), 4.00-3.73 (m, 4H), 3.57-3.41 (m, 2H); 31P NMR
(D2O) δ 8.08 (d, J = 19.1 Hz), 1.90-0.02 (br), −10.48 (s), −10.74 (s); HRMS-EI found
790.9233 (M-H+)−. C16H26N2O22P4Cl requires 790.9227; purity > 98% by HPLC (System
A: 10.3 min).
General procedure for the preparation of nucleoside tetraphosphate sugars (28–37)
The appropriate sugar 63 – 67 was treated with a mixture of sodium acetate (50 mg) in
acetic anhydride (5 mL), and the mixture was stirred for 5 h at 110°C while following the
course of the reaction by TLC. Excess Ac2O was removed using a rotary evaporator, and the
mixture was stirred with aq. NaHCO3 for 15 min. The product was extracted into
dichloromethane and washed with brine. The corresponding crude acetyl derivative was
purified by column chromatography. The monophosphate derivatives (68– 72) of these
acetyl sugars were prepared as the lithium salts using the MacDonald procedure.39 The
corresponding sugar monophosphate (0.036 mmol) and uridine triphosphate trisodium salt
(10 mg, 0.018 mmol) were converted to the tributylammonium salts by treatment with ion-
exchange resin (DOWEX 50WX2-200 (H)) and tri-n-butylamine. After removal of the
water, the obtained tributylammonium salts were dried under high vacuum for 1 h. DIC
(3.05 µL, 0.036 mmol) was added to a solution of 1 as a tributylammonium salt (0.018
mmol) in DMF (0.2 mL). After stirring the reaction mixture at rt for 3 h, a solution of the
corresponding sugar monophosphate tributylammonium salt (0.036 mmol), and MgCl2 (3.43
mg, 0.036 mmol) in DMF (0.1 mL) was added. The reaction mixture was stirred at rt for 2 h
to overnight. After removal of the solvent, the MgCl2 was removed by treatment with ion-
exchange resin (DOWEX 50WX2-200 (H)) and ammonia bicarbonate or tri-n-butylamine,
and the residue was purified by a semipreparative HPLC purification using system C.
Uridine-5′-allose-1′-tetraphosphate triethylammonium salt (28)—Compound 28
(1 mg, 8%) was obtained as a white solid using 1 (10 mg, 0.018 mmol) and D-allose-1-
phosphate (69, 16.5 mg, 0.036 mmol). 1H NMR (D2O) δ 7.95 (d, J = 8.1 Hz, 1H), 5.98 (m,
2H), 5.60 (m, 1H), 4.16 (m, 2H), 4.33 (m, 1H), 4.28-4.23 (m, 2H), 3.90-3.60 (m, 4H), 3.54
(m, 1H), 3.41 (m, 1H); 31P NMR (D2O) δ −11.29 (m), −12.40 (m), −22.86 (m); HRMS-EI
found 724.9831 (M-H)+. C15H25N2O23P4 requires 724.9804; HPLC (purity 97%, System A:
11.5 min; purity 98%, System B: 0.8 min).
Uridine-5′-mannose-1′-tetraphosphate triethylammonium salt (29)—Compound
29 (3.18 mg, 24%) was obtained as a white solid using 1 (10 mg, 0.018 mmol) and D-
mannose-1-phosphate (68, 16.5 mg, 0.036 mmol). 1H NMR (D2O) δ 7.99 (d, J = 8.4 Hz,
1H), 6.02 (m, 2H), 5.56 (m, 1H), 4.44 (m, 2H), 4.31-4.27 (m, 3H), 4.16 (m, 1H), 4.03-3.87
(m, 3H), 3.79 (m, 1H), 3.67 (m, 1H); 31P NMR (D2O) δ −11.17 (d, J = 17.6 Hz), −12.63 (d,
J = 17.5 Hz), −23.10 (m); HRMS-EI found 724.9796 (M-H)+. C15H25N2O23P4 requires
724.9799; HPLC (purity 99%, System A: 10.4 min; purity 99%, System B: 1.1 min).
Uridine-5′-xylose-1′-tetraphosphate triethylammonium salt (30)—Compound 30
(3.18 mg, 43%) was obtained as a white solid using 1 (6.3 mg, 0.011 mmol) and D-xylose-1-
phosphate (14 mg, 0.032 mmol). 1H NMR (D2O) δ 8.00 (d, J = 8.4 Hz, 1H), 6.07-5.98 (m,
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2H), 5.64-5.58 (m, 1H), 4.50-4.40 (m, 2H), 4.36-4.23 (m, 3H), 3.83-3.76 (m, 1H), 3.69-3.60
(m, 1H), 3.58-3.49 (m, 1H), 3.47-3.37 (m, 1H); 31P NMR (D2O) δ −11.22 (d, J = 16.8 Hz),
−12.65 (d, J = 18.2 Hz), −22.6 – −23.4 (m); HRMS-EI found 694.9693 (M-H)−.
C14H23N2O22P4 requires 694.9656; purity > 98% by HPLC (System B: 12.3 min).
General procedure for the preparation of nucleoside tetraphosphate sugars (31 and 32)
The corresponding sodium salt of sugar monophosphate (0.036 mmol) and the trisodium salt
of 1 (10 mg, 0.018 mmol) were converted to the tributylammonium salts by treatment with
ion-exchange resin (DOWEX 50WX2-200 (H)) and tri-n-butylamine. After removal of the
water, the obtained tributylammonium salts were dried under high vacuum 1 h. DIC (3.05
µL, 0.036 mmol) was added to a solution of 1 as a tributylammonium salt (0.018 mmol) in
DMF (0.2 mL). After stirring the reaction mixture at rt for 3 h, a solution of the
corresponding sugar monophosphate tributylammonium salt (0.036 mmol) and MgCl2 (3.43
mg, 0.036 mmol) in DMF (0.1 mL) was added. The reaction mixture was stirred at rt for 2 h
to overnight. After removal of the solvent, the MgCl2 was removed by treatment with ion-
exchange resin (DOWEX 50WX2-200 (H)) and ammonia bicarbonate or tri-n-butylamine,
and the residue was purified by a semipreparative HPLC purification using system C.
P1-(Uridine-5′-)P4-(2’-deoxy-2′-acetamidoglucose-1′-)tetraphosphate
triethylammonium salt (31)—Compound 31 (5.21 mg, 38%) was obtained as a white
solid using 1 (10 mg, 0.018 mmol) and D-2-deoxy-2-acetamidoglucose-1-phosphate (12.5
mg, 0.036 mmol). 1H NMR (D2O) δ 7.99 (d, J = 8.1 Hz, 1H), 6.02 (m, 2H), 5.53 (m, 1H),
4.44 (m, 2H), 4.29 (m, 3H), 4.02-3.80 (m, 4H), 3.53 (m, 1H), 2.11 (s, 3H), 1.93 (s, 1H); 31P
NMR (D2O) δ −11.17 (d, J = 18.3 Hz), −12.77 (d, J = 19.0 Hz), −23.10 (m); HRMS-EI
found 766.0037 (M-H)+. C17H28N3O23P4 requires 766.0064; HPLC (purity 99%, System A:
10.4 min; purity 99%, System B: 0.8 min).
P1-(Uridine-5′-)P4-(glucuronic acid-1′-)tetraphosphate triethylammonium salt
(32)—Compound 32 (2.46 mg, 18%) was obtained as a white solid using 1 (10 mg, 0.018
mmol) and α-D-glucuronic acid 1-phosphate (74, 12.2 mg, 0.036 mmol). 1H NMR (D2O) δ
7.95 (d, J = 7.5 Hz, 1H), 5.99 (m, 2H), 5.65 (m, 1H), 4.39 (m, 2H), 4.27-4.23 (m, 3H), 4.10
(m, 1H), 3.80 (m, 1H), 3.51 (s, 2H); 31P NMR (D2O) δ −11.18 (d, J = 17.6 Hz), −12.55 (d, J
= 16.7 Hz), −22.71 (m); HRMS-EI found 738.9575 (M-H)+. C175H23N2O24P4 requires
738.9591; HPLC (purity 97%, System A: 11.4 min; purity 99%, System B: 1.0 min).
P1-(Uridine-5′-)P4-(2′-deoxy-2′-fluoroglucose-1′-)tetraphosphate
triethylammonium salt (33)—Compound 33 (3.28 mg, 25%) was obtained as a white
solid using 1 (10 mg, 0.018 mmol) and D-2-deoxy-2-fluoroglucose-1-phosphate (70, 16.57
mg, 0.036 mmol). 1H NMR (D2O) δ 7.99 (d, J = 8.1 Hz, 1H), 6.01 (m, 2H), 5.82 (m, 1H),
4.44 (m, 2H), 4.28 (m, 3H), 4.12-3.71 (m, 4H), 3.52 (m, 1H); 31P NMR (D2O) δ −11.10 (d,
J = 16.7 Hz), −13.10 (d, J = 17.5 Hz), −23.07 (m); HRMS-EI found 726.9753 (M-H)+.
C15H24FN2O23P4 requires 726.9761; HPLC (purity 99%, System A: 10.3 min; purity 98%,
System B: 1.1 min).
P1-(Uridine-5′-)P4-(3′-deoxy-3′-fluoroglucose-1′-)tetraphosphate
triethylammonium salt (34)—Compound 34 (3.58 mg, 27%) was obtained as a white
solid using 1 (10 mg, 0.018 mmol) and D-3-deoxy-3-fluoroglucose-1-phosphate (71, 16.57
mg, 0.036 mmol). 1H NMR (D2O) δ 7.92 (d, J = 8.1 Hz, 1H), 5.98 (m, 2H), 5.61 (m, 1H),
4.35 (m, 2H), 4.27-4.21 (m, 4H), 3.99-3.72 (m, 3H); 31P NMR (D2O) δ −11.08 (m), −12.87
(m), −22.38 (m); HRMS-EI found 726.9763 (M-H)+. C15H24FN2O23P4 requires 726.9761;
HPLC (purity 98%, System A: 10.4 min; purity 98%, System B: 1.0 min).
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triethylammonium salt (35)—Compound 35 (0.550 mg, 2.6%) was obtained as a white
solid using triethylammonium salt of N4-benzyloxycytidine 5′-triphosphate (14.45 mg, 0.018
mmol) and D-3-deoxy-3-fluoroglucose-1-phosphate (71, 14.76 mg, 0.036 mmol). 1H NMR
(D2O) δ 7.44 (m, 5H), 7.23 (d, J = 8.8 Hz, 1H), 5.96 (d, J = 6.4 Hz, 1H), 5.77 (d, J = 8.4 Hz,
1H), 5.05 (s, 2H), 4.46-4.42 (m, 2H), 4.38-4.17 (m, 4H), 3.99-3.72 (m, 3H); 31P NMR
(D2O) δ −11.53 (m), −13.27 (m), −23.21 (m); HRMS-EI found 832.0319 (M-H)+.
C22H31FN3O22P4 requires 726.9761.
P1-(N4-Methoxycytidine-5′-)P4-(3′-deoxy-3′-fluoroglucose-1′-)tetraphosphate
triethylammonium salt (36)—Compound 36 (0.80 mg, 8.8%) was obtained as a white
solid using triethylammonium salt of N4-methoxycytidine 5′-triphosphate (9 mg, 0.012
mmol) and D-3-deoxy-3-fluoroglucose-1-phosphate (71, 10 mg, 0.025 mmol). 1H NMR
(D2O) δ 7.26 (d, J = 7.6 Hz, 1H), 5.96 (d, J = 6.92 Hz, 1H), 5.83 (d, J = 8.2 Hz, 1H), 5.69
(m, 1H), 4.42-4.37 (m, 2H), 4.26-4.15 (m, 4H), 3.99-3.89 (m, 2H), 3.80 (m, 5H); HRMS-EI
found 756.0002 (M-H)+. C16H27FN3O24P4 requires 756.0021; purity 97% by HPLC
(System B: 13.5 min).
P1-(Uridine-5′-)P4-(4′-deoxy-4′-fluoroglucose-1′-)tetraphosphate
triethylammonium salt (37)—Compound 37 (2.88 mg, 22%) was obtained as a white
solid using 1 (10 mg, 0.018 mmol) and D-4-deoxy-4-fluoroglucose-1-phosphate (72, 16.57
mg, 0.036 mmol). 1H NMR (D2O) δ 7.99 (d, J = 8.1 Hz, 1H), 6.02 (m, 2H), 5.66 (m, 1H),
4.45 (m, 2H), 4.28 (m, 3H), 4.17-4.06 (m, 2H), 3.99-3.77 (m, 2H), 3.60 (m, 1H); 31P NMR
(D2O) δ −11.12 (d, J = 17.6 Hz), −12.70 (d, J = 16.6 Hz), −23.17 (m); HRMS-EI found
726.9753 (M-H)+. C15H24FN2O23P4 requires 726.9761; HPLC (purity 97%, System A: 11.0
min; purity 99%, System B: 1.1 min).
α-D-Glucuronic acid 1-phosphate trisodium salt (74)
TEMPO (10 mg, 64 µmol) was added to a solution of α-D-glucose-1-phosphate disodium
salt (73, 4.13 g, 13.6 mmol) in H2O (4 mL) at 0°C. To this solution, aqueous 1 M NaOH
was added until pH 9 was reached, and a NaOCl solution (1.2 mL, available chlorine: 10–
13%) was added slowly. The pH was maintained at 9 by adding 1 M NaOH aq. several times
during the reaction. After 1.5 h, MeOH was added to the reaction mixture, and the resulting
precipitate was collected by filtration to give 74 (415 mg, 90%) as a white solid. 1H-NMR
(D2O) δ5.46 (dd, 1H, J=3.6, 7.5 Hz), 4.15 (d, 1H, J=10.2 Hz), 3.79 (t, 1H, J=9.6 Hz), 3.48
(d, 1H, J=9.6 Hz), 3.47 (t, 1H, J=9.6 Hz); HRMS-ES− found 294.9831 (M+Na−2H)−.
C6H9O10PNa requires 294.9837.
Assay of PLC activity stimulated by P2Y2, P2Y4, and P2Y6 receptors
Stable cell lines expressing the human P2Y2, P2Y4, or P2Y6 receptor in 1321N1 human
astrocytoma cells were generated as described.19 Agonist-induced [3H]inositol phosphate
production was measured in in 96-well plates that received 20,000 cells/well two days prior
to assay. Sixteen h before the assay, the inositol lipid pool of the cells was radiolabeled by
incubation in 100 µL of serum-free inositol-free Dulbecco's modified Eagle's medium,
containing 1.0 µCi of myo-[3H]inositol. No changes of medium were made subsequent to
the addition of [3H]inositol. On the day of the assay, cells were challenged with 25 µL of a
five-fold concentrated solution of receptor agonists in 200 mM HEPES (N-(2-
hydroxyethyl)-piperazine-N′-2-ethanesulfonic acid), pH 7.3 in Hank's balanced salt solution,
containing 50 mM LiCl for 30 min at 37°C. Incubations were terminated by aspiration of the
drug-containing medium and addition of 450 µL of ice-cold 50 mM formic acid.
[3H]Inositol phosphate accumulation was quantified using scintillation proximity assay
methodology as previously described in detail.19
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Agonist potencies (EC50 values) were determined from concentration-response curves by
non-linear regression analysis using the GraphPad software package Prism (GraphPad, San
Diego, CA). All experiments examining the activity of newly synthesized molecules also
included full concentration effect curves for the cognate agonist of the target receptor: 1 for
the P2Y2 and P2Y4 receptors and UDP for the P2Y6 receptor. Each concentration of drug
was tested in triplicate assays, and concentration effect curves for each test drug were
repeated in at least three separate experiments with freshly diluted molecule. The results are
presented as mean ± SEM from multiple experiments or in the case of concentration effect
curves from a single experiment carried out with triplicate assays that were representative of
results from multiple experiments.
Molecular Modeling
Molecular models of the P2Y2 and P2Y4 receptors were constructed with the Molecular
Operating Environment (MOE)40 on the basis of the crystal structure of the CXCR4
chemokine receptor.16 An initial sequence alignment was obtained with the Blosum62
substitution matrix, with penalties for gap insertions and extensions of 7 and 1, respectively.
The proper alignment of the conserved motifs that characterize each of the TM helices was
checked and, when necessary, manually adjusted. All the gaps in the alignment of the TM
helices were eliminated; gaps in the loops were consolidated into a single gap per loop, and
positioned where insertions or deletions seemed compatible with the structure of the
template. The final alignment used for the construction of the model is provided in Figure 3.
Ten models were built and scored on the basis of electrostatic solvation energy (GB/VI).41
Intermediate and final models were subjected to energy minimizations with the Amber99
force field, according to the protocol implemented in MOE, with the refinement level set to
medium.40
As mentioned, a disulfide bridge connects the N-terminus and the extracellular end of TM7
in the CXCR4 receptor and, putatively, in the P2Y receptors, according to mutagenesis
data.22–24 However, as evident from Figure 3, in the P2Y receptors this cysteine residue is
shifted two residues downstream with respect to the CXCR4 receptor. Thus, before the
construction of the homology model, the N-terminal region of the template was modified ad
hoc. In particular, Cys28 and Arg30 of CXCR4 were mutated to alanine and cysteine,
respectively, and a disulfide bridge was built between Cys28 and Cys274. The mutated
CXCR4 receptor was then subjected to energy minimization with MOE,37 with the
Amber99 force field, until reaching a cutoff parameter on the potential energy gradient of
0.05 kcal/(mol·Å). During the minimization, the two cysteines and all the N-terminal
residues were granted flexibility.
After the construction of the homology models, 1 was docked into the P2Y2 and P2Y4
receptors superimposing our previously published complexes to the new models. For each
receptor, the ligand was then subjected to two subsequent energy minimizations, the first
holding the receptor frozen, the second one granting flexibility to all residues within a 5 Å
radius from the ligand. The energy minimizations were conducted in MOE,40 with the
MMFFx force field, until reaching a cutoff parameter on the potential energy gradient of
0.05 kcal/(mol·Å). Compounds 11 and 16 were then sketched from 1 within the P2Y2 and
P2Y4 receptors, respectively, and subsequently subjected to the same two rounds of
minimization following the same protocol outlined above for 1. The obtained P2Y2-11 and
P2Y4-16 complexes were subsequently transferred to Maestro42 and subjected to
conformational searches with the MacroModel engine,43 as implemented in the Schrodinger
package. Flexibility was granted to the ligands and the residues within a 5 Å radius from
them. All of the atoms within an additional shell of a 3 Å radius were also taken into account
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as a frozen environment. The calculations were conducted with the MMFFs force field,
using water as implicit solvent (GB/SA model).44 The minimizations were based on the
Polak-Ribiere conjugate gradient algorithm and were performed with a threshold on the
potential energy gradient of 0.05 kcal/(mol·Å). The conformational searches were based on
100 steps of extended Monte Carlo Multiple Minimum (MCMM) sampling protocol.
Specifically, the sampling regarded all torsion angles of residues and ligands, as well as
ligand rotation and ligand translation.
The interhelical cavities of the P2Y2 and P2Y4 receptor were analyzed with the SiteMap
program, implemented in the Schrodinger package, cropping site maps at 2 Å from the
nearest site point.44
Stability of Nucleotide Derivatives
Compound 1 was purchased from Sigma (St. Louis, MO). Compound 2 was synthesized by
the procedure previously reported.13 HCl buffer (pH 1.5) solution was prepared as follows.
Concentrated HCl (7 mL, 12 N) was added to 2.0 g of sodium chloride and diluted with
water to a volume of 1000 mL. Membranes were prepared as follows. P2Y1 receptor-
expressing astrocytoma cells were grown to 80% confluence and then harvested. The cells
were homogenized and the nuclear fraction was removed by centrifuging at 100 × g for 5
min. The pellet was resuspended in 50 mM tris(hydroxymethyl)aminomethane (Tris)
hydrochloride buffer (pH 7.4). The suspension was homogenized with a polytron
homogenizer (Brinkmann) for 10 s and was ultracentrifuged at 20,000 × g for 20 min at 4°C.
The resultant pellets were resuspended in Tris buffer (pH 7.4), and the membrane was stored
at −80° C until the experiments. The protein concentration of the membrane preparation was
measured using the Bradford assay.45 The membrane preparation was diluted with 4 mL of
Dulbecco’s phosphate-buffered saline (pH 7.4) and homogenized before use for the stability
check. The final protein concentration was 14.9 µg/mL.
Ten µL of a 2 mg/mL aqueous solution of each nucleotide derivative was mixed with either
90 µL of HCl buffer (pH 1.2) or the membrane suspension and incubated at 37°C. At regular
intervals, a 6 µL aliquot of the above mixture (either membranes or low pH) removed. The
injection sample was pre-diluted with 54 µL of 5 mM tetrabutylammonium
dihydrogenphosphate (TBAP) to allow complete equilibration with the mobile phase to
avoid the early HPLC elution at ~1 min. Then, 50 µL of the mixture was injected to the
HPLC.
AUC of compounds were measured using a Hewlett–Packard 1100 HPLC equipped with a
Zorbax Eclipse 5 mm XDB-C18 analytical column (250 × 4.6 mm; Agilent Technologies
Inc, Palo Alto, CA). Mobile phase: linear gradient solvent system: 5 mM TBAP-CH3CN
from 80:20 to 40:60 in 6.5 min; the flow rate was 1 mL/min (System C) or System B. Peaks
were detected by UV absorption with a diode array detector at 254, 275, and 280 nm and
AUC were calculated based on the peak at 254 nm.
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HPLC high performance liquid chromatography
IL intracellular loop
MOE Molecular Operating Environment










X-ray determination was performed by Dr. Yoshiaki Oyama, Asubio Pharmaceuticals, Osaka, Japan. Mass spectral
measurements were performed by Dr. Noel Whittaker (NIDDK). We thank Dr. Francesca Deflorian (NIDDK) and
Dr. Andrei A. Ivanov (Emory Univ.) for helpful discussions. This research was supported in part by NIGMS
research grant GM38213 and by the Intramural Research Program of NIDDK, National Institutes of Health. H.
Maruoka thanks Asubio Pharma Co., Ltd. for financial support. S. de Castro thanks Ministerio de Educacio´n y
Ciencia (Spain) for financial support.
References
1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Fumagalli M,
King BF, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII:
update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and
pathophysiology to therapy. Pharmacol. Rev. 2006; 58:281–341. [PubMed: 16968944]
2. Brunschweiger A, Müller CE. P2 Receptors activated by uracil nucleotides - An update. Current
Med. Chem. 2006; 13:289–312.
3. Nicholas RA, Lazarowski ER, Watt WC, Li Q, Harden TK. Uridine nucleotide selectivity of three
phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an
ATP- and UTP-specific receptor. Mol. Pharmacol. 1996; 50:224–229. [PubMed: 8700127]
4. Communi D, Motte S, Boeynaems JM, Pirotton S. Pharmacological characterization of the human
P2Y4 receptor. Eur. J. Pharmacol. 1996; 317:383–389. [PubMed: 8997625]
5. Shaver SR, Rideout JL, Pendergast W, Douglass JG, Brown EG, Boyer JL, Patel RI, Redick CC,
Jones AC, Picher M, Yerxa BR. Structure activity relationships of dinucleotides: Potent and
selective agonists of P2Y receptors. Purinergic Signalling. 2005; 1:183–191. [PubMed: 18404503]
6. Yerxa BR, Sabater JR, Davis CW, Stutts MJ, Lang-Furr M, Picher M, Jones AC, Cowlen M,
Dougherty R, Boyer J, Abraham WM, Boucher RC. Pharmacology of INS37217 [P(1)-(uridine 5’)-
P(4)- (2’-deoxycytidine 5’)tetraphosphate, tetrasodium salt], a next-generation P2Y2 receptor
agonist for the treatment of cystic fibrosis. J. Pharmacol. Exp. Ther. 2002; 302:871–880. [PubMed:
12183642]
Maruoka et al. Page 16













7. Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden A, Smiley L. Denufosol: A review of
studies with inhaled P2Y2 agonists that led to Phase 3. Pulm. Pharmacol. Ther. 2008; 21:600–607.
[PubMed: 18276176]
8. Jacobson K, Costanzi S, Ivanov A, Tchilibon S, Besada P, Gao Z, Maddileti S, Harden T. Structure
activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate
analogues at the human P2Y2 and P2Y4 receptors. Biochem. Pharmacol. 2006; 71:540–549.
[PubMed: 16359641]
9. Davenport RJ, Diaz P, Galvin FC, Lloyd S, Mack SR, Owens R, Sabin V, Wynn J. Novel nucleotide
triphosphates as potent P2Y2 agonists with enhanced stability over UTP. Bioorg. Med. Chem. Lett.
2007; 17:558–561. [PubMed: 17079144]
10. Ivanov A, Ko H, Cosyn L, Maddileti S, Besada P, Fricks I, Costanzi S, Harden T, Calenbergh S,
Jacobson K. Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-
amino-2'-deoxy-2-thiouridine 5'-triphosphate. J. Med. Chem. 2007; 50:1166–1176. [PubMed:
17302398]
11. Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg A-K, Erlinge D, Malmsjö M, Boyer JL,
Harden TK, Jacobson KA. Methanocarba modification of uracil and adenine nucleotides: High
potency of Northern ring conformation at P2Y1, P2Y2, P2Y4 and P2Y11, but not P2Y6 receptors.
J. Med. Chem. 2002; 45:208–218. [PubMed: 11754592]
12. El-Tayeb A, Qi A, Müller CE. Synthesis and Structure-Activity Relationships of Uracil Nucleotide
Derivatives and Analogues as Agonists at Human P2Y2, P2Y4, and P2Y6 Receptors. J. Med.
Chem. 2006; 49:7076–7087. [PubMed: 17125260]
13. Ko H, Carter RL, Cosyn L, Petrelli R, de Castro S, Besada P, Zhou Y, Cappellacci L, Franchetti P,
Grifantini M, Van Calenbergh S, Harden TK, Jacobson KA. Synthesis and potency of novel uracil
nucleotide analogues as P2Y2 and P2Y6 receptor agonists. Bioorg. Med. Chem. 2008; 16:6319–
6332. [PubMed: 18514530]
14. Sauer R, El-Tayeb A, Kaulich M, Müller CE. Synthesis of uracil nucleotide analogs with a
modified, acyclic ribose moiety as P2Y2 receptor antagonists. Bioorg. Med. Chem. 2009;
17:5071–5079. [PubMed: 19523835]
15. Maruoka H, Barrett MO, Ko H, Tosh DK, Melman A, Burianek LE, Balasubramanian R, Berk B,
Costanzi S, Harden TK, Jacobson KA. Pyrimidine Ribonucleotides with Enhanced Selectivity as
P2Y6 Receptor Agonists: Novel 4-Alkyloxyimino, (S)-Methanocarba, and 5’-Triphosphate γ-Ester
Modifications. J. Med. Chem. 2010; 53:4488–4501. [PubMed: 20446735]
16. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC,
Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC. Structures of the CXCR4 chemokine
GPCR with small-molecule and cyclic peptide antagonists. Science. 2010; 330:1066–1071.
[PubMed: 20929726]
17. Kogo S, Yamada K, Iwai Y, Osawa K, Hayakawa H. Process for Producing Di(pyrimidine
nucleoside 5’-)polyphosphate. 2008 WO2008/012949 A1.
18. Heeres A, van Doren HA, Gotlieb KF, Bleeker IP. Synthesis of α- and β- D- glucopyranuronate 1-
phosphate and α-D-glucopyranuronate 1-fluoride: Intermediates in the synthesis of D-glucuronic
acid from starch. Carbohydrate Res. 1997; 299:221–227.
19. Bourdon DM, Wing MR, Edwards EB, Sondek J, Harden TK. Quantification of isozyme-specific
activation of phospholipase C-β 2 by Rac GTPases and phospholipase C-ε by Rho GTPases in an
intact cell assay system. Methods Enzymol. 2006; 406:489–499. [PubMed: 16472681]
20. Costanzi S, Mamedova L, Gao Z, Jacobson K. Architecture of P2Y nucleotide receptors: structural
comparison based on sequence analysis, mutagenesis, and homology modeling. J. Med. Chem.
2004; 47:5393–5404. [PubMed: 15481977]
21. de Castro S, Maruoka H, Hong K, Kilbey SM 2nd, Costanzi S, Hechler B, Brown GG Jr, Gachet C,
Harden TK, Jacobson KA. Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-
methanocarba 2'-deoxyadenosine 3',5'-bisphosphate analogues and conjugation to a
polyamidoamine (PAMAM) dendrimer carrier. Bioconjugate Chem. 2010; 21:1190–205.
22. Hoffmann C, Moro S, Nicholas RA, Harden TK, Jacobson KA. The role of amino acids in
extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J.
Biol. Chem. 1999; 274:14639–14647. [PubMed: 10329657]
Maruoka et al. Page 17













23. Moro S, Hoffmann C, Jacobson KA. Role of the extracellular loops of G protein- coupled receptors
in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry.
1999; 38:3498–3507. [PubMed: 10090736]
24. Hillmann P, Ko GY, Spinrath A, Raulf A, von Kugelgen I, Wolff SC, Nicholas RA, Kostenis E,
Holtje HD, Muller CE. Key determinants of nucleotide-activated G protein-coupled P2Y2 receptor
function revealed by chemical and pharmacological experiments, mutagenesis and homology
modeling. J. Med. Chem. 2009; 52:2762–2775. [PubMed: 19419204]
25. Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA. Human P2Y1 receptor:
molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist
recognition sites. J. Med. Chem. 1998; 41:1456–66. [PubMed: 9554879]
26. Jiang Q, Guo D, Lee BX, van Rhee AM, Kim YC, Nicholas RA, Schachter JB, Harden TK,
Jacobson KA. A mutational analysis of residues essential for ligand recognition at the human
P2Y1 receptor. Mol. Pharmacol. 1997; 52:499–507. [PubMed: 9281613]
27. Van Meervelt L. Structure of 3’,5’-di-O-acetyl-N4-methoxycytosine. Acta Cryst. 1991; C47:2635–
2637.
28. Ballesteros, JA.; Weinstein, H. Integrated methods for the construction of three-dimensional
models and computational probing of structure-function relations in G protein-coupled receptors.
In: Stuart, CS., editor. Methods in Neurosciences. Vol. 25. Academic Press; 1995. p. 366-428.
29. van Rhee AM, Jacobson KA. Molecular architecture of G protein-coupled receptors. Drug
Develop. Res. 1996; 37:1–38.
30. Costanzi S, Tikhonova I, Ohno M, Roh E, Joshi B, Colson A, Houston D, Maddileti S, Harden T,
Jacobson K. P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative
prediction of the biological activity based on consensus scoring. J. Med. Chem. 2007; 50:3229–
3241. [PubMed: 17564423]
31. Yitzhaki S, Shneyvais V, Jacobson KA, Shainberg A. Involvement of uracil nucleotides in
protection of cardiomyocytes from hypoxic stress. Biochem. Pharmacol. 2005; 69:1215–1223.
[PubMed: 15794942]
32. Wildman SS, Unwin RJ, King BF. Extended pharmacological profiles of rat P2Y2 and rat P2Y4
receptors and their sensitivity to extracellular H+ and Zn2+ ions. Br. J. Pharmacol. 2003;
140:1177–1186. [PubMed: 14581177]
33. Robaye B, Ghanem E, Wilkin F, Fokan D, Van Driessche W, Schurmans S, Boeynaems JM,
Beauwens R. Loss of nucleotide regulation of epithelial chloride transport in the jejunum of P2Y4-
null mice. Mol. Pharmacol. 2003; 63:777–783. [PubMed: 12644577]
34. Ghanem E, Robaye B, Leal T, Leipziger J, Van Driessche W, Beauwens R, Boeynaems JM. The
role of epithelial P2Y2 and P2Y4 receptors in the regulation of intestinal chloride secretion. Br. J.
Pharmacol. 2005; 146:364–369. [PubMed: 16056234]
35. Matos JE, Sorensen MV, Geyti CS, Robaye B, Boeynaems JM, Leipziger J. Distal colonic Na+
absorption inhibited by luminal P2Y2 receptors. Pflugers Arch. 2007; 454:977–987. [PubMed:
17356885]
36. Cosentino, S.; Barcella, S.; Lo, H.; Burbiel, JC.; Müller, CE.; Tremoli, E.; Banfi, C.; Abbracchio,
MP. Purines. Tarragona, Spain: 2010. Role of P2 receptors in a cardiomyocyte ischemic hypoxia
model. May 30 – June 2, 2010 Abstract P10-11
37. Horckmans M, Lantz N, Dol-Gleizes F, Savi P, Gachet C, Boeynaems JM, Robaye B, Communi
D. Involvement of the P2Y4 receptor in inflammation and angiogenesis. Purines 2008 Meeting 29
June – 2 July 2008, Copenhagen, Denmark. Purinergic Signal. 2008; 4 Suppl 1:118.
38. Vanderstocken G, Bondue B, Horckmans M, Di Pietrantonio L, Robaye B, Boeynaems JM,
Communi D. P2Y2 receptor regulates VCAM-1 membrane and soluble forms and eosinophil
accumulation during lung inflammation. J. Immunol. 2010; 185:3702–3707. [PubMed: 20720203]
39. MacDonald DL. Chemical synthesis of aldose 1-phosphates. Methods Enzymol. 1966; 8:121–125.
[11].
40. The molecular operating environment (MOE). Chemical Computing Group, Inc; Montreal,
Canada: 2009.10, www.ccg.com
Maruoka et al. Page 18













41. Labute P. The generalized Born/volume integral implicit solvent model: estimation of the free
energy of hydration using London dispersion instead of atomic surface area. J. Comput. Chem.
2008; 29:1693–1698. [PubMed: 18307169]
42. Maestro. Schrodinger, LLC; New York, NY, USA: 9.1, www.schrodinger.com
43. MacroModel. Schrodinger, LLC; New York, NY, USA: 9.8, www.schrodinger.com
44. SiteMap. Schrödinger, LLC; New York, NY, USA: 2.4, www.schrodinger.com
45. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein
utilizing the principle of protein dye binding. Anal. Biochem. 1976; 76:248–254. [PubMed:
942051]
Maruoka et al. Page 19














Activity of native agonist 1 and alklyoxyimino derivatives 14, 15, and 16 at the P2Y4
receptor as indicated by activation of PLC in 1321N1 human astrocytoma cells stably
expressing the human P2Y4 receptor.
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Activity of compound 16 (N4-(phenylpropoxy)-CTP) at P2Y2, P2Y4, and P2Y6 receptors as
indicated by activation of PLC in 1321N1 human astrocytoma cells stably expressing the
human P2Y2, P2Y4, or P2Y6 receptor. The effect of 1 corresponds to 100%.
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Rhodopsin-based molecular models of the P2Y2 and P2Y4 receptors.20 The second
extracellular loop (EL2) is schematically represented as a green tube. The area that in these
models would surround the N4-substituents of the imino derivatives described in this article
is completely conserved between the P2Y2 and P2Y4 receptor. This is in contrast with the
fact that large N4substituents are better tolerated by the P2Y4 than the P2Y2 receptor. Two
non-conserved EL2 residues that could explain the selectivity profile of the N4-substituents
compounds according to the CXCR4 models (see Figures 5) are not positioned in a way that
would allow interactions with such moieties in the rhodopsin-based models. Receptor
residues are represented with gray carbons, while ligands are represented with yellow
carbons. See Figure of Jacobson et al.8 for further details on the rhodopsin-based models.
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Sequence alignment of CXCR4, P2Y2, and P2Y4 receptors used for the construction of the
homology models. The sequence of the P2Y1 receptor, on which most of the mutagenesis
studies were performed, is also shown. Green dots indicate the two non-conserved EL2
residues putatively responsible for the selectivity of compound 16 for the P2Y4 receptor.
Blue dots indicate the conserved cationic residues putatively responsible for coordination of
the negatively charged phosphate groups of the ligands. An additional cationic residue,
Lys2897.36 of the P2Y4 receptor, is proposed to interact with the α-phosphate. The cysteine
residues involved in the formation of disulfide bridges are encased in a dark yellow box and
connected by a dark yellow line. The glutamate and arginine residues involved in the
formation of the salt bridge that putatively connects EL2 to the extracellular end of TM6,
conserved also in the P2Y1 receptor, are encased in a red and a blue box, respectively, and
are connected by a red and blue line. The secondary structure of the template is indicated by
a color-coded bar, with α-helices in red, β-strands in yellow and turns in blue. For each TM,
black dots indicate the X.50 position, as defined in the GPCR indexing system.
Transmembrane helices (TMs), extracellular loops (ELs) and intracellular loops (ILs) are
indicated by labels. The figure was generated with MOE.40
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Contour of interhelical cavity (in gray) of the P2Y2 and P2Y4 receptor deduced from the
analysis of the new CXCR4 homology models. According to these models, there is only one
region, indicated by a dashed yellow circle, where the cavity is significantly smaller in the
P2Y2 than in the P2Y4 receptor. This difference is due to a non-conserved amino acid in
EL2, which is a threonine (Thr182) in the P2Y4 receptor and a bulkier arginine (Arg180) in
the P2Y2 receptor. Of note, an arginine residue is present at the corresponding position of
the CXCR4 receptor (Arg183). The orientation of Arg180 in our model of the P2Y2 receptor
follows the orientation of Arg183 in the crystal structure of the CXCR4 receptor. The
disulfide bridge that putatively links the N-terminus with EL3 and the salt bridge that
putatively links TM6 with EL2 are shown. The disulfide bridge that links TM3 with EL2 is
not clearly visible because it is obscured by the interhelical cavity. Compounds 11 and 16
are shown within the pockets of the P2Y2 and P2Y4 receptors, respectively. The backbone
of the receptor is schematically represented as a ribbon colored with a continuum spectrum
going from red, at the N-terminus, to purple, at the C-terminus. For convenience, TM7 is not
shown.
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Previously published rhodopsin-based model (Panel A, in complex with 1) and new
CXCR4-based model of the P2Y4 receptor (Panel B, in complex with 16). One residue of
the CXCR4 receptor (Tyr1163.32, in red) was key to deduce the putative rotameric state of
the corresponding residue in the P2Y2 and P2Y4 receptors (Phe1133.32 for P2Y2 and
Phe1153.32 for P2Y4, in gray) in the new models. The CXCR4-based rotameric state of
Phe3.32 caused a significant change of the ligand binding mode with respect to the
previously published one. The backbone of TM3 is schematically represented as a yellow
ribbon.
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A) Time-course of the hydrolysis of various nucleotides incubated at 37°C and pH 1.5. The
assays were started with 0.2 mg/mL of the compound. Concentration of analogues in the
medium was determined using HPLC analysis of aliquots. Data are expressed as percent of
the initial peak. B) Time-course of the degradation of various nucleotides in the presence of
membranes of 1321N1 astrocytoma cells. The cells were homogenized and the nuclear
fraction was removed by centrifugation. The resultant pellets were suspended in Tris buffer
(pH 7.4). The membrane was diluted with Dulbecco’s PBS (pH 7.4) and homogenized
before use for the stability check. The final protein concentration was 14.9 µg/mL. The
assays were started with 0.2 mg/mL compound. Concentrations of molecules were analyzed
using HPLC. Data are expressed as percent of initial peak.
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Synthesis of alkoxyimino derivatives. Reagents and conditions: i) RONH2, pyridine, 100°C,
overnight; ii) a) Proton Sponge, POCl3, PO(OMe)3, 0°C, 3 h, b) Bu3N, tributylammonium
pyrophosphate, 0,°C, 10 min, c) triethylammonium bicarbonate aq., rt, 30 min.
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Synthesis of aryl phosphates. Reagents and conditions: i) CBr4, iPr2NEt, dibenzyl phosphite,
MeCN, rt, 2 h; ii) TMS-Br, CH2Cl2, rt, 1.5 h.
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Synthesis of sugar-1-phosphates. Reagents and conditions: i) Ac2O, NaOAc, 5 h, 110°C; ii)
H3PO4, 50°C, 3 h; iii) TEMPO, H2O, NaOH, NaOCl, 0°C.
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Synthesis of β, γ-dichloromethylene-UTP 10. Reagents and conditions: from 75, i) a) DIC,
DMF, rt, 3 h; b) PO(OH)2CCl2PO(OH)2, MgCl2, DMF, rt, overnight; from 76, ii)
PO(OH)2CCl2PO(OH)2, DMF, rt, 2 weeks.
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Synthesis of Up4-δ-phenyl ester derivatives. Reagents and conditions: i) a) DIC, DMF, rt, 3
h; b) aryl-1-phosphate, MgCl2, DMF, rt, overnight.
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Synthesis of Up4-δ-sugar derivatives. Reagent and condition: i) a) DIC or DCC, DMF, rt, 3
h; b) sugar-1-phosphate, MgCl2, DMF, rt, 2 h to overnight. Unless noted, Y = O.
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Structures and potencies of prototypical agonist ligands for studying P2Y2 and P2Y4
receptors.
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